PITTSBURGH, Feb. 24, 2012
PITTSBURGH, Feb. 24, 2012 /PRNewswire/ --Â Mylan Inc. (Nasdaq: MYL) today announced that Tony Mauro, president of Mylan North America and the company's Mylan Pharmaceuticals subsidiary, has been elected to serve as chairman of the Generic Pharmaceutical Association's (GPhA) board of directors. GPhA is an association that represents the world's leading generic drug manufacturers and suppliers. Mauro's election to this role further supports Mylan's mission to impact the future through passionate global leadership on the important issues and policies that shape the generic pharmaceuticals industry.
Mauro said: "I would like to thank the GPhA board of directors and membership for this opportunity, and also acknowledge Ralph Neas for his strong leadership of GPhA since joining the organization. I sincerely look forward to serving as chair and continuing to work closely with the board and Ralph during this truly monumental era in our industry. With growing populations, economic recessions and increasing health care costs, the need for widespread access to more affordable medicine has never been so great. The generic pharmaceutical industry, which accounts for 78% of all prescriptions dispensed in the U.S., has played an important role in saving the U.S. health care system and consumers an estimated $931 billion over the past decade."
"Generic drug makers also have stepped forward to assist the Food and Drug Administration (FDA) in addressing the industry-wide challenges, experienced by both brand and generics companies, caused by the globalization of the drug supply chain and the corresponding increase in the FDA's workload. This effort positions GPhA at the forefront of our industry's important issues, and advises policy makers that they should look to us as a key partner when tackling current and future challenges."
Mauro's term as chairman of GPhA will last for one year. Previously, he served two one-year terms as the vice chairman of the association. In his 15 years at Mylan, Mauro has held roles of increasing responsibility across the company's business units, including president of Mylan Pharmaceuticals, chief operating officer for Mylan Pharmaceuticals ULC in Canada, vice president of Strategic Development, North America, and vice president of Sales, North America.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.
SOURCE Mylan Inc.PR Newswire
Last updated on: 24/02/2012